Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


2 BJU Int
1 BMC Cancer
2 Cancer Lett
2 Int J Urol
1 J Magn Reson Imaging
7 J Urol
1 Lancet Oncol
1 Nat Rev Urol
2 Oncogene
1 Oncol Rep
3 Prostate
2 Urol Int
1 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BJU Int

  1. GRAY WK, Day J, Briggs TWR, Harrison S, et al
    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
    BJU Int. 2022;129:93-103.
    PubMed         Abstract available

  2. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
    The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
    BJU Int. 2021;128 Suppl 3:45-51.
    PubMed         Abstract available

    BMC Cancer

  3. COUDERC AL, Villani P, Berbis J, Nouguerede E, et al
    HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
    BMC Cancer. 2022;22:78.
    PubMed         Abstract available

    Cancer Lett

  4. KANG J, La Manna F, Bonollo F, Sampson N, et al
    Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
    Cancer Lett. 2022 Jan 17. pii: S0304-3835(22)00023.
    PubMed         Abstract available

  5. QIAN C, Li D, Chen Y
    ETS factors in prostate cancer.
    Cancer Lett. 2022 Jan 13. pii: S0304-3835(22)00017.
    PubMed         Abstract available

    Int J Urol

  6. MOROZUMI K, Mitsuzuka K, Narita S, Takahashi M, et al
    Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score >/=8.
    Int J Urol. 2022 Jan 18. doi: 10.1111/iju.14781.
    PubMed         Abstract available

  7. YAMASHITA S, Kawabata H, Deguchi R, Ueda Y, et al
    Myosteatosis as a novel predictor of urinary incontinence after robot-assisted radical prostatectomy.
    Int J Urol. 2022;29:34-40.
    PubMed         Abstract available

    J Magn Reson Imaging

  8. KLINGEBIEL M, Schimmoller L, Weiland E, Franiel T, et al
    Value of T2 Mapping MRI for Prostate Cancer Detection and Classification.
    J Magn Reson Imaging. 2022 Jan 17. doi: 10.1002/jmri.28061.
    PubMed         Abstract available

    J Urol

  9. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
    Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
    J Urol. 2022;207:118-126.
    PubMed         Abstract available

  10. CHANG P, Wagner AA, Regan MM, Smith JA, et al
    Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
    J Urol. 2022;207:127-136.
    PubMed         Abstract available

  11. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
    Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
    J Urol. 2022;207:95-107.
    PubMed         Abstract available

  12. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    J Urol. 2022;207:108-117.
    PubMed         Abstract available

  13. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
    Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
    J Urol. 2021;206:1403-1410.
    PubMed         Abstract available

  14. WANG M, Semerjian A, Lane BR, George AK, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
    J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.

  15. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
    J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
    PubMed         Abstract available

    Lancet Oncol

  16. KISHAN AU, Sun Y, Hartman H, Pisansky TM, et al
    Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
    Lancet Oncol. 2022 Jan 17. pii: S1470-2045(21)00705.
    PubMed         Abstract available

    Nat Rev Urol

  17. MUNGOVAN SF, Carlsson SV, Gass GC, Graham PL, et al
    Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy.
    Nat Rev Urol. 2021;18:259-281.
    PubMed         Abstract available


  18. XU L, Zhao B, Butler W, Xu H, et al
    Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.
    Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02155.
    PubMed         Abstract available

  19. CANNISTRACI A, Hascoet P, Ali A, Mundra P, et al
    MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
    Oncogene. 2022 Jan 17. pii: 10.1038/s41388-022-02178.
    PubMed         Abstract available

    Oncol Rep

  20. ZHAO J, Li Q, Feng B, Wei D, et al
    MicroRNA149 inhibits cancer cell malignant phenotype by regulating Akt1 in C42 CRPC cell line.
    Oncol Rep. 2021;46.
    PubMed         Abstract available


  21. ZHOU J, Chen H, Wu Y, Shi B, et al
    Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
    PubMed         Abstract available

  22. ZHU S, Zhang Z, Zhang H, Liu Z, et al
    DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
    PubMed         Abstract available

  23. MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
    Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
    PubMed         Abstract available

    Urol Int

  24. PRATSINIS M, Babst C, Langenauer J, Schmid HP, et al
    Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions.
    Urol Int. 2021;105.
    PubMed         Abstract available

  25. MASSANOVA M, Robertson S, Barone B, Dutto L, et al
    The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study.
    Urol Int. 2021;105.
    PubMed         Abstract available


  26. KOTAMARTI S, George A, Zhu A, Polascik TJ, et al
    Transrectal Ultrasound-Guided Biopsy Should Continue to Be a Standard of Care for The Detection of Prostate Cancer.
    Urology. 2022 Jan 14. pii: S0090-4295(22)00018.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.